CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer

Published:2020-04-03 Issue:6 Volume:125 Page:817-826
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Mostafid A. Hugh¹^ORCID,Porta Nuria²,Cresswell Joanne³,Griffiths Thomas R.L.⁴,Kelly John D.⁵,Penegar Steven R.²,Davenport Kim⁶,McGrath John S.⁷,Campain Nicholas⁷,Cooke Peter⁸,Masood Shikohe⁹,Knowles Margaret A.¹⁰,Feber Andrew⁵,Knight Allen¹¹,Catto James W.F.¹²,Lewis Rebecca²,Hall Emma²^ORCID

Affiliation:

1. Royal Surrey County Hospital NHS Foundation Trust; Guildford UK

2. Institute of Cancer Research; London UK

3. South Tees Hospitals NHS Foundation Trust; Middlesbrough UK

4. University Hospitals of Leicester NHS Trust; Leicester UK

5. University College London; London UK

6. Gloucestershire Hospitals NHS Foundation Trust; Cheltenham UK

7. Royal Devon and Exeter NHS Foundation Trust; Exeter UK

8. Royal Wolverhampton Hospitals NHS Trust; Wolverhampton UK

9. Medway NHS Foundation Trust; Gillingham UK

10. University of Leeds; Leeds UK

11. Action Bladder Cancer UK; Gloucestershire UK

12. University of Sheffield; Sheffield UK

Funder

National Institute for Health Research

Cancer Research UK

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.15038/fullpdf

Reference18 articles.

1. Bladder cancer incidence and mortality: a global overview and recent trends;Antoni;Eur Urol,2017

2. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update;Babjuk;Eur Urol,2019

3. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance;Linton;J Urol,2013

4. Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) urological tumour registry;Boustead;BJU Int,2014

5. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients;Noon;Br J Cancer,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group;Journal of Clinical Oncology;2023-12-10

2. Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial;European Urology;2023-11

3. First-line Intravesical Chemotherapy for Non–muscle-invasive Bladder Cancer: Chimera or “Ne Plus Ultra”?;European Urology;2023-07

4. Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen’s Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206–11;European Urology;2023-04

5. Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00470;European Urology;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3